{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T05:38:03Z","timestamp":1775885883700,"version":"3.50.1"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T00:00:00Z","timestamp":1723248000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Current data on fosfomycin usage in children are limited. We present data on the clinical use of intravenous (IV) fosfomycin in children. Hospitalized patients who received \u22653\u2009days of IV fosfomycin between April 2021 and March 2023 were analyzed retrospectively. Forty-three episodes of infection in 39 patients were evaluated. The mean age of the patients was 5.35 (10\u2009days to 17.5\u2009years) years, and 54% were male. Infections were hospital-acquired in 79% of the episodes. Indications for fosfomycin were urinary tract infection (35%), bacteremia (32.6%), catheter-related bloodstream infection (16.3%), soft tissue infection (4.7%), sepsis (4.7%), surgical site infection (2.3%), burn infection (2.3%), and pneumonia (2.3%). Klebsiella pneumoniae was identified in 46.5% of the episodes, and a pan-drug or extensive drug resistance was detected in 75% of them. Carbapenem was used before fosfomycin at significantly higher rates in K. pneumoniae episodes (P\u2009=\u2009.006). Most (88.5%) patients received fosfomycin as a combination therapy. Culture negativity was achieved in 80% of episodes within a median treatment period of 3 (2\u201322) days, which was significantly shorter in K. pneumoniae episodes (P\u2009&amp;lt;\u2009.001). Treatment-related side effects were seen in 9.3% of the episodes. Side effects were significant after 3 weeks of treatment (P\u2009=\u2009.013). The unresponsivity rate to fosfomycin was 23.3%. Nine (21%) of the patients who were followed up in the intensive care units mainly died because of sepsis (56%). IV fosfomycin is an effective agent in treating severe pediatric infections caused by resistant microorganisms. Fosfomycin can be used in various indications and is generally safe for children.<\/jats:p>","DOI":"10.1093\/tropej\/fmae029","type":"journal-article","created":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T11:46:26Z","timestamp":1725536786000},"source":"Crossref","is-referenced-by-count":1,"title":["Intravenous fosfomycin indications and treatment outcomes in pediatric usage: analysis from a single center in Turkey"],"prefix":"10.1093","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2538-2872","authenticated-orcid":false,"given":"Saliha","family":"Kan\u0131k-Y\u00fcksek","sequence":"first","affiliation":[{"name":"Department of Pediatric Infectious Disease, University of Health Sciences, Ankara Bilkent City Hospital , Ankara 06800, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7121-3810","authenticated-orcid":false,"given":"\u00d6mer","family":"G\u00fcne\u015f","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Disease, University of Health Sciences, Ankara Bilkent City Hospital , Ankara 06800, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0839-1301","authenticated-orcid":false,"given":"Belgin","family":"G\u00fclhan","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Disease, University of Health Sciences, Ankara Bilkent City Hospital , Ankara 06800, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2434-4134","authenticated-orcid":false,"given":"Tu\u011fba","family":"Erat","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Disease, University of Health Sciences, Ankara Bilkent City Hospital , Ankara 06800, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7235-4217","authenticated-orcid":false,"given":"Hatice K\u00fcbra","family":"Konca","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Disease, University of Health Sciences, Ankara Bilkent City Hospital , Ankara 06800, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8342-3786","authenticated-orcid":false,"given":"Seval","family":"\u00d6zen","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Disease, University of Health Sciences, Ankara Bilkent City Hospital , Ankara 06800, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7245-2028","authenticated-orcid":false,"given":"Aysun","family":"Yah\u015fi","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Disease, University of Health Sciences, Ankara Bilkent City Hospital , Ankara 06800, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1423-4348","authenticated-orcid":false,"given":"G\u00fcls\u00fcm \u0130clal","family":"Bayhan","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Disease, Ankara Y\u0131ld\u0131r\u0131m Beyaz\u0131t University, Ankara Bilkent City Hospital , Ankara 06800, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5691-2461","authenticated-orcid":false,"given":"Asl\u0131nur","family":"\u00d6zkaya-Parlakay","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Disease, Ankara Y\u0131ld\u0131r\u0131m Beyaz\u0131t University, Ankara Bilkent City Hospital , Ankara 06800, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"2024090420355055500_fmae029-B1","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jiac.2016.01.010","article-title":"Fosfomycin: resurgence of an old companion","volume":"22","author":"Sastry","year":"2016","journal-title":"J Infect Chemother"},{"key":"2024090420355055500_fmae029-B2","doi-asserted-by":"crossref","first-page":"a025262","DOI":"10.1101\/cshperspect.a025262","article-title":"Fosfomycin: mechanism and resistance","volume":"7","author":"Silver","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"Suppl 1","key":"2024090420355055500_fmae029-B3","first-page":"55","article-title":"Fosfomycin in the pediatric setting: evidence and potential indications","volume":"32","author":"Baquero-Artigao","year":"2019","journal-title":"Rev Esp Quimioter"},{"key":"2024090420355055500_fmae029-B4","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1111\/jpc.14883","article-title":"Potential of fosfomycin in treating multidrug-resistant infections in children","volume":"56","author":"Williams","year":"2020","journal-title":"J Paediatr Child Health"},{"key":"2024090420355055500_fmae029-B5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1099\/jmm.0.000973","article-title":"The potential of fosfomycin for multi-drug resistant sepsis: an analysis of in vitro activity against invasive pediatric Gram-negative bacteria","volume":"68","author":"Williams","year":"2019","journal-title":"J Med Microbiol"},{"key":"2024090420355055500_fmae029-B6","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.cmi.2016.12.005","article-title":"Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature","volume":"23","author":"Grabein","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"2024090420355055500_fmae029-B7","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pan drug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2024090420355055500_fmae029-B8","author":"EUCAST"},{"key":"2024090420355055500_fmae029-B9","author":"WHO"},{"key":"2024090420355055500_fmae029-B10","author":"WHO","year":"2023"},{"key":"2024090420355055500_fmae029-B11","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1007\/s15010-019-01323-4","article-title":"Current clinical use of intravenous fosfomycin in ICU patients in two European countries","volume":"47","author":"Putensen","year":"2019","journal-title":"Infection"},{"key":"2024090420355055500_fmae029-B12","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1111\/bcp.14456","article-title":"Physiologically based pharmacokinetic-pharmacodynamic evaluation of meropenem plus fosfomycin in pediatrics","volume":"87","author":"Martins","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2024090420355055500_fmae029-B13","doi-asserted-by":"crossref","first-page":"E 0029321","DOI":"10.1128\/AAC.00293-21","article-title":"Amikacin combined with fosfomycin for treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance","volume":"65","author":"Darlow","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2024090420355055500_fmae029-B14","first-page":"acmi000163","article-title":"Use of fosfomycin combination therapy to treat multidrug-resistant urinary tract infection among paediatric surgical patients\u2014a tertiary care centre experience","volume":"2","author":"Shiju","year":"2020","journal-title":"Access Microbiol"},{"key":"2024090420355055500_fmae029-B15","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1086\/527442","article-title":"Fosfomycin: use beyond urinary tract and gastrointestinal infections","volume":"46","author":"Falagas","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"2024090420355055500_fmae029-B16","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1159\/000222084","article-title":"Antibiotherapy of Serratia marcescens septicemia in children","volume":"23","author":"Baquero","year":"1977","journal-title":"Chemotherapy"},{"key":"2024090420355055500_fmae029-B17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin Microbiol Rev"},{"key":"2024090420355055500_fmae029-B18","doi-asserted-by":"crossref","first-page":"844122","DOI":"10.3389\/fphar.2022.844122","article-title":"Hypernatremia during intravenous treatment with fosfomycin: a retrospective medical record review study and an analysis of spontaneous reports in the EudraVigilance database","volume":"13","author":"Scavone","year":"2022","journal-title":"Front Pharmacol"},{"key":"2024090420355055500_fmae029-B19","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1016\/j.ijid.2011.07.007","article-title":"The revival of fosfomycin","volume":"15","author":"Michalopoulos","year":"2011","journal-title":"Int J Infect Dis"},{"key":"2024090420355055500_fmae029-B20","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1080\/14787210.2021.1932463","article-title":"Intravenous fosfomycin for the treatment of patients with bone and joint infections: a review","volume":"20","author":"Tsegka","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2024090420355055500_fmae029-B21","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/archdischild-2021-322483","article-title":"Randomized controlled trial of fosfomycin in neonatal sepsis: pharmacokinetics and safety in relation to sodium overload","volume":"107","author":"Obiero","year":"2022","journal-title":"Arch Dis Child"},{"key":"2024090420355055500_fmae029-B22","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1097\/INF.0000000000004263","article-title":"Back to the future: intravenous fosfomycin is safe and effective for the treatment of complicated infections in children","volume":"43","author":"Roversi","year":"2024","journal-title":"Pediatr Infect Dis J"}],"container-title":["Journal of Tropical Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/tropej\/article-pdf\/70\/5\/fmae029\/59022025\/fmae029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/tropej\/article-pdf\/70\/5\/fmae029\/59022025\/fmae029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T11:46:42Z","timestamp":1725536802000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/tropej\/article\/doi\/10.1093\/tropej\/fmae029\/7749541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,10]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2024,8,10]]}},"URL":"https:\/\/doi.org\/10.1093\/tropej\/fmae029","relation":{},"ISSN":["0142-6338","1465-3664"],"issn-type":[{"value":"0142-6338","type":"print"},{"value":"1465-3664","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,8,10]]},"article-number":"fmae029"}}